Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C.

The cytochrome P450s responsible for the regio- and stereoselectivity in the 2- and 3-hydroxylation of the chiral non-steroidal antiinflammatory drug ibuprofen were characterized in human liver microsomes. The rates of formation of both the 2- and 3-hydroxy metabolites exhibited monophasic (N = 2; N is the number of microsomal preparations) and biphasic (N = 2) substrate concentration dependence for both enantiomers of ibuprofen. The high affinity enzyme class parameters for S-ibuprofen (N = 4) were: 2-hydroxylation, Vmax = 566 +/- 213 pmol/min/mg, Km = 38 +/- 13 microM; 3-hydroxylation, Vmax = 892 +/- 630 pmol/min/mg, Km = 21 +/- 6 microM. For R-ibuprofen, the corresponding parameters were: 2-hydroxylation, Vmax = 510 +/- 117 pmol/min/mg, Km = 47 +/- 20 microM; 3-hydroxylation, Vmax = 593 +/- 113 pmol/min/mg, Km = 29 +/- 8 microM. cDNA-expressed CYP2C9 (Arg 144 and Cys 144) favored S-2- and S-3-hydroxyibuprofen formation, but CYP2C8 favored R-2-hydroxyibuprofen formation. Sulfaphenazole, retinol, and arachidonic acid competitively inhibited the rate of formation of all hydroxyibuprofens; Ki values (N = 3) for sulfaphenazole on the 2- and 3-hydroxylations of S-ibuprofen were 0.12 +/- 0.05 and 0.07 +/- 0.04 and of R-ibuprofen were 0.11 +/- 0.07 and 0.06 +/- 0.03 microM, respectively. Sulfaphenazole also competitively inhibited ibuprofen hydroxylation by cDNA-expressed CYP2C9 (Arg 144 and Cys 144) with Ki values in the range of 0.05 to 0.18 microM and CYP2C8 in the range of 0.36 to 0.55 microM. In a bank of 14 human liver microsome samples, significant correlations (r = 0.72 to 0.90; P < 0.01) were observed between the rates of formation of all four hydroxyibuprofens, and for each hydroxyibuprofen and prototypical CYP2C8/9 biotransformations. The regio- and stereoselectivities observed in vitro were consistent with those noted in vivo. The relative levels of both CYP2C8 and CYP2C9 and the expression of the corresponding variants may influence the disposition of ibuprofen in vivo.

[1]  L. Wienkers,et al.  Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[2]  D M Clive,et al.  Renal syndromes associated with nonsteroidal antiinflammatory drugs. , 1984, The New England journal of medicine.

[3]  J. Miners,et al.  Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.

[4]  J. Goldstein,et al.  Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. , 1993, Molecular pharmacology.

[5]  K. Korzekwa,et al.  Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. , 1994, Cancer research.

[6]  M. Lai,et al.  Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. , 1995, Pharmacogenetics.

[7]  R. Branch,et al.  Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. , 1987, The Journal of pharmacology and experimental therapeutics.

[8]  C. Lieber,et al.  Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. , 1989, Archives of biochemistry and biophysics.

[9]  S D Hall,et al.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[10]  R. Tukey,et al.  Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. , 1994, Biochemical pharmacology.

[11]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[12]  P. Bonnabry,et al.  A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. , 1993, Drugs under experimental and clinical research.

[13]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[14]  H. Dirven,et al.  Determination of the cytochrome P-450 IV marker, omega-hydroxylauric acid, by high-performance liquid chromatography and fluorimetric detection. , 1991, Journal of chromatography.

[15]  S. Adams,et al.  The metabolism of ibuprofen. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[17]  D. Koop,et al.  Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. , 1994, The Journal of pharmacology and experimental therapeutics.

[18]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[19]  M. Relling,et al.  Variability in human cytochrome P450 paclitaxel metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.

[20]  J. Mcgiff,et al.  The contribution of cytochrome P450-dependent arachidonate metabolites to integrated renal function , 1993, Steroids.

[21]  S. Abramson,et al.  Modes of action of aspirin-like drugs. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Wechter,et al.  Isomeric inversion of ibuprofen (R)-enantiomer in humans. , 1976, Journal of pharmaceutical sciences.

[23]  M. Hampton,et al.  Indomethacin in submicromolar concentrations inhibits cyclic AMP-dependent protein kinase , 1978, Nature.

[24]  M. T. Gilbert,et al.  Studies of urinary metabolites of 2-(4-isobutylphenyl) propionic acid by gas-liquid chromatography-mass spectrometry. , 1974, Journal of chromatography.

[25]  B. Ring,et al.  In vitro methods for assessing human hepatic drug metabolism: their use in drug development. , 1993, Drug metabolism reviews.

[26]  R. DuBois,et al.  Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. , 1995, Archives of biochemistry and biophysics.

[27]  S. Waldman,et al.  A mutation in CYP2C9 is responsible for decreased metabolism of losartan , 1996 .

[28]  S. Hall,et al.  Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen. , 1991, The Journal of pharmacology and experimental therapeutics.

[29]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[30]  M. Murray,et al.  Renal toxicity of the nonsteroidal anti-inflammatory drugs. , 1993, Annual review of pharmacology and toxicology.

[31]  D. Brater,et al.  Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment. , 1995, The Journal of pharmacology and experimental therapeutics.

[32]  S. Adams,et al.  Pharmacological differences between the optical isomers of ibuprofen: evidence for metabolic inversion of the (—)‐isomer , 1976, The Journal of pharmacy and pharmacology.

[33]  R. Day,et al.  Stereoselective disposition of ibuprofen enantiomers in infants. , 1985 .